Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three antibiotics—ceftriaxone, penicillin, and gentamicin—used together for the treatment of severe bacterial infections. Each component has a distinct mechanism of action: - **Ceftriaxone** is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death. It has broad-spectrum activity against many Gram-negative and some Gram-positive bacteria. - **Penicillin** (referring generally to the class or specific agents like benzylpenicillin) also inhibits bacterial cell wall synthesis via binding to penicillin-binding proteins, primarily effective against Gram-positive organisms. - **Gentamicin** is an aminoglycoside antibiotic that binds irreversibly to the 30S subunit of the bacterial ribosome, inhibiting protein synthesis and causing misreading of mRNA. The combination may be used in clinical scenarios such as infective endocarditis or other serious infections where synergistic effects are desired for enhanced bactericidal activity. The addition of gentamicin can provide synergy with beta-lactam antibiotics (like ceftriaxone or penicillins), especially against certain streptococci or enterococci[1][6]. However, this triple combination is not standard for most indications; more commonly used combinations include either ceftriaxone plus gentamicin or penicillin plus gentamicin[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ceftriaxone + penicillin + gentamicin.